GLPwatch
Papers (10404)
Page 75 of 174, ranked by citation count.
- Exendin-4 ameliorates diabetic symptoms through activation of glucokinase.
- Efficacy and Safety of Multiple Doses of Exenatide Once-Monthly Suspension in Patients With Type 2 Diabetes: A Phase II Randomized Clinical Trial.
- Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database.
- Effectiveness of tirzepatide in patients with HFpEF using a target trial emulation retrospective cohort study.
- Challenges with glucagon-like peptide-1 (GLP-1) agonist initiation: a case series of semaglutide overdose administration errors.
- Differing effects of liraglutide on gastric emptying in Japanese patients with type 2 diabetes.
- Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence.
- Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential.
- Factors Affecting the Timing of Signal Detection of Adverse Drug Reactions.
- Exenatide alleviates adriamycin-induced heart dysfunction in mice: Modulation of oxidative stress, apoptosis and inflammation.
- Ecological momentary assessment and cue-elicited drug craving as primary endpoints: study protocol for a randomized, double-blind, placebo-controlled clinical trial testing the efficacy of a GLP-1 receptor agonist in opioid use disorder.
- Exendin-4 antagonizes the metabolic action of acylated ghrelinergic signaling in the hypothalamic paraventricular nucleus.
- Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial.
- Effect of GLP-1RA Treatment on Adhesion Molecules and Monocyte Chemoattractant Protein-1 in Diabetic Patients with Atherosclerosis.
- Clinical effectiveness of tirzepatide for patients with atrial fibrillation and type 2 diabetes: A retrospective cohort study.
- Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial.
- A physiological role of glucagon-like peptide-1 receptors in the central nervous system of Suncus murinus (house musk shrew).
- Novel Site-Specific Fatty Chain-Modified GLP-1 Receptor Agonist with Potent Antidiabetic Effects.
- Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis.
- The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting.
- Peptide ligations accelerated by N-terminal aspartate and glutamate residues.
- Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin.
- Liraglutide in adults with type 2 diabetes: global perspective on safety, efficacy and patient preference.
- Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity.
- Exploring the potential impact of GLP-1 receptor agonists in cancer therapy.
- Cross-sectional, case-control and longitudinal associations between exposure to glucagon-like peptide-1 receptor agonists and the dispensing of antidepressants.
- Semaglutide outperforms insulin in restoring neutrophil function against implant-related infection in diabetic and obese mice: experimental research.
- Obestatin can potentially differentiate Wharton's jelly mesenchymal stem cells into insulin-producing cells.
- Induction of apolipoprotein A-I gene expression by glucagon-like peptide-1 and exendin-4 in hepatocytes but not intestinal cells.
- Liraglutide, a GLP-1 Receptor Agonist, Which Decreases Hypothalamic 5-HT2A Receptor Expression, Reduces Appetite and Body Weight Independently of Serotonin Synthesis in Mice.
- GLP-1 receptor signaling restores aquaporin 4 subcellular polarization in reactive astrocytes and promotes amyloid β clearance in a mouse model of Alzheimer's disease.
- GLP-1 preserves β cell function via improvement on islet insulin signaling in high fat diet feeding mice.
- The role of gut microbiota in Tirzepatide-mediated alleviation of high-fat diet-induced obesity.
- Effects of GLP-1 Receptor Agonists in Alcohol Use Disorder.
- Effects of GLP-1 receptor agonists on asprosin levels in normal weight or overweight/obesity patients with type 2 diabetes mellitus.
- A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy.
- The influence of age and metformin treatment status on reported gastrointestinal side effects with liraglutide treatment in type 2 diabetes.
- Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats.
- Hypothalamic obesity after craniopharyngioma surgery: Treatment with a long acting glucagon like peptide 1 derivated.
- Clinical Impact of Tirzepatide on Patients With OSA and Obesity.
- The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome.
- Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting.
- Exendin-4, a glucagon-like peptide-1 analogue accelerates healing of chronic gastric ulcer in diabetic rats.
- Cardiovascular outcomes and safety with antidiabetic drugs.
- Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration.
- The Effects of Cardioprotective Antidiabetic Therapy on Microbiota in Patients with Type 2 Diabetes Mellitus-A Systematic Review.
- Protective Effects of Liraglutide and Linagliptin in C. elegans as a New Model for Glucose-Induced Neurodegeneration.
- In vitro and in vivo sustained release of exenatide from vesicular phospholipid gels for type II diabetes.
- Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight.
- Exenatide preserves trabecular bone microarchitecture in experimental ovariectomized rat model.
- Systemic Allergic Reaction to the GLP-1 Receptor Agonist Exenatide.
- Exenatide-loaded inside-porous poly(lactic-co-glycolic acid) microspheres as a long-acting drug delivery system with improved release characteristics.
- Liraglutide pharmacokinetics and dose-exposure response in Asian subjects with Type 2 diabetes from China, India and South Korea.
- More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L.
- Glucagon-like Peptide-1 Agonists: What the Orthopaedic Surgeon Needs to Know.
- Therapeutic Potential of Liraglutide for Diabetes-Periodontitis Comorbidity: Killing Two Birds with One Stone.
- Long-term feeding on powdered food causes hyperglycemia and signs of systemic illness in mice.
- Exendin‑4 promotes osteogenic differentiation of adipose‑derived stem cells and facilitates bone repair.
- Glucagon-like peptide-1 receptor agonists and reduced mortality, cardiovascular and psychiatric risks in patients with psoriasis: a large-scale cohort study.
- A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the Treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health.